NCT01053312View on ClinicalTrials.gov

PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

August 31, 2010

Conditions
Normal Pressure Hydrocephalus
Interventions
DRUG

[18F] Flutemetamol

All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).

Trial Locations (1)

08540

GE Healthcare, Princeton

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
collaborator

i3 Statprobe

INDUSTRY

lead

GE Healthcare

INDUSTRY